Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.

Buchalski B, Wood KD, Challa A, Fargue S, Holmes RP, Lowther WT, Knight J.

Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165633. doi: 10.1016/j.bbadis.2019.165633. Epub 2019 Dec 7.

PMID:
31821850
2.

Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Torres JA, Rezaei M, Broderick C, Lin L, Wang X, Hoppe B, Cowley BD Jr, Savica V, Torres VE, Khan S, Holmes RP, Mrug M, Weimbs T.

J Clin Invest. 2019 Jul 30;130:4506-4522. doi: 10.1172/JCI128503.

3.

Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.

Wood KD, Holmes RP, Erbe D, Liebow A, Fargue S, Knight J.

Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2203-2209. doi: 10.1016/j.bbadis.2019.04.017. Epub 2019 May 2.

PMID:
31055082
4.

Dietary oxalate and kidney stone formation.

Mitchell T, Kumar P, Reddy T, Wood KD, Knight J, Assimos DG, Holmes RP.

Am J Physiol Renal Physiol. 2019 Mar 1;316(3):F409-F413. doi: 10.1152/ajprenal.00373.2018. Epub 2018 Dec 19. Review.

PMID:
30566003
5.

Accuracy in 24-hour Urine Collection at a Tertiary Center.

Boyd C, Wood K, Whitaker D, Ashorobi O, Harvey L, Oster R, Holmes RP, Assimos DG.

Rev Urol. 2018;20(3):119-124. doi: 10.3909/riu0807.

6.

Modeling the structural and dynamical changes of the epithelial calcium channel TRPV5 caused by the A563T variation based on the structure of TRPV6.

Wang L, Holmes RP, Peng JB.

J Biomol Struct Dyn. 2019 Aug;37(13):3506-3512. doi: 10.1080/07391102.2018.1518790. Epub 2018 Dec 10.

PMID:
30175942
7.

Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.

Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP.

J Am Soc Nephrol. 2018 Jun;29(6):1615-1623. doi: 10.1681/ASN.2017040390. Epub 2018 Mar 27.

8.

Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line.

Patel M, Yarlagadda V, Adedoyin O, Saini V, Assimos DG, Holmes RP, Mitchell T.

Redox Biol. 2018 May;15:207-215. doi: 10.1016/j.redox.2017.12.003. Epub 2017 Dec 15.

9.

The L530R variation associated with recurrent kidney stones impairs the structure and function of TRPV5.

Wang L, Holmes RP, Peng JB.

Biochem Biophys Res Commun. 2017 Oct 21;492(3):362-367. doi: 10.1016/j.bbrc.2017.08.102. Epub 2017 Aug 25.

10.

Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass.

Moreland AM, Santa Ana CA, Asplin JR, Kuhn JA, Holmes RP, Cole JA, Odstrcil EA, Van Dinter TG Jr, Martinez JG, Fordtran JS.

Gastroenterology. 2017 Apr;152(5):1055-1067.e3. doi: 10.1053/j.gastro.2017.01.004. Epub 2017 Jan 12.

PMID:
28089681
11.

RNA interference in the treatment of renal stone disease: Current status and future potentials.

Wood KD, Holmes RP, Knight J.

Int J Surg. 2016 Dec;36(Pt D):713-716. doi: 10.1016/j.ijsu.2016.11.027. Epub 2016 Nov 12. Review.

12.

An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J.

J Am Soc Nephrol. 2017 Feb;28(2):494-503. doi: 10.1681/ASN.2016030338. Epub 2016 Jul 18.

13.

Ascorbic acid intake and oxalate synthesis.

Knight J, Madduma-Liyanage K, Mobley JA, Assimos DG, Holmes RP.

Urolithiasis. 2016 Aug;44(4):289-97. doi: 10.1007/s00240-016-0868-7. Epub 2016 Mar 22. Review.

14.

Monocyte Mitochondrial Function in Calcium Oxalate Stone Formers.

Williams J, Holmes RP, Assimos DG, Mitchell T.

Urology. 2016 Jul;93:224.e1-6. doi: 10.1016/j.urology.2016.03.004. Epub 2016 Mar 10.

15.

Oxalate Concentrations in Human Gastrointestinal Fluid.

Reddy TG, Knight J, Holmes RP, Harvey LM, Mitchem AL, Wilcox CM, Monkemuller KE, Assimos DG.

J Endourol. 2016 May;30 Suppl 1:S8-11. doi: 10.1089/end.2015.0838. Epub 2016 Mar 30.

PMID:
26943671
16.

Proteome Dynamics of the Specialist Oxalate Degrader Oxalobacter formigenes.

Ellis ME, Mobley JA, Holmes RP, Knight J.

J Proteomics Bioinform. 2016;9(1):19-24.

17.

Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.

Fargue S, Knight J, Holmes RP, Rumsby G, Danpure CJ.

Biochim Biophys Acta. 2016 Jun;1862(6):1055-62. doi: 10.1016/j.bbadis.2016.02.004. Epub 2016 Feb 6.

18.

Molecular Modeling of the Structural and Dynamical Changes in Calcium Channel TRPV5 Induced by the African-Specific A563T Variation.

Wang L, Holmes RP, Peng JB.

Biochemistry. 2016 Mar 1;55(8):1254-64. doi: 10.1021/acs.biochem.5b00732. Epub 2016 Feb 15.

19.

Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.

Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP.

Biochim Biophys Acta. 2016 Feb;1862(2):233-9. doi: 10.1016/j.bbadis.2015.12.001. Epub 2015 Dec 2.

20.

Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.

Holmes RP, Knight J, Assimos DG.

Urolithiasis. 2016 Feb;44(1):27-32. doi: 10.1007/s00240-015-0839-4. Epub 2015 Nov 27. Review.

21.

Oxalate Formation From Glyoxal in Erythrocytes.

Knight J, Wood KD, Lange JN, Assimos DG, Holmes RP.

Urology. 2016 Feb;88:226.e11-5. doi: 10.1016/j.urology.2015.10.014. Epub 2015 Nov 4.

22.

Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3.

Li X, Knight J, Todd Lowther W, Holmes RP.

Biochim Biophys Acta. 2015 Dec;1852(12):2700-5. doi: 10.1016/j.bbadis.2015.09.016. Epub 2015 Sep 30.

23.

Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.

Summitt CB, Johnson LC, Jönsson TJ, Parsonage D, Holmes RP, Lowther WT.

Biochem J. 2015 Mar 1;466(2):273-81. doi: 10.1042/BJ20141159.

24.

A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II.

Fu Y, Rope R, Fargue S, Cohen HT, Holmes RP, Cohen DM.

Clin Genet. 2015 Nov;88(5):494-8. doi: 10.1111/cge.12541. Epub 2014 Dec 26.

25.

Reply: To PMID 25102784.

Lange JN, Mufarrij PW, Easter L, Knight J, Holmes RP, Assimos DG.

Urology. 2014 Oct;84(4):782. doi: 10.1016/j.urology.2014.04.054. Epub 2014 Aug 5. No abstract available.

PMID:
25102790
26.

Fish oil supplementation and urinary oxalate excretion in normal subjects on a low-oxalate diet.

Lange JN, Mufarrij PW, Easter L, Knight J, Holmes RP, Assimos DG.

Urology. 2014 Oct;84(4):779-81. doi: 10.1016/j.urology.2014.04.052. Epub 2014 Aug 5.

27.

Internet program for facilitating dietary modifications limiting kidney stone risk.

Lange JN, Easter L, Amoroso R, Benfield D, Mufarri PW, Knight J, Holmes RP, Assimos DG.

Can J Urol. 2013 Oct;20(5):6922-6.

28.

The genetic composition of Oxalobacter formigenes and its relationship to colonization and calcium oxalate stone disease.

Knight J, Deora R, Assimos DG, Holmes RP.

Urolithiasis. 2013 Jun;41(3):187-96. doi: 10.1007/s00240-013-0566-7. Epub 2013 Apr 30. Review.

29.

The effects of Oxazyme on oxalate degradation: results and implications of in vitro experiments.

Mufarrij PW, Lange JN, Knight J, Assimos DG, Holmes RP.

J Endourol. 2013 Mar;27(3):284-7. doi: 10.1089/end.2012.0214. Epub 2012 Dec 7.

PMID:
22966963
30.

4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition.

Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT.

Biochim Biophys Acta. 2012 Oct;1822(10):1544-52. doi: 10.1016/j.bbadis.2012.06.014. Epub 2012 Jul 5.

31.

Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics.

Lange JN, Wood KD, Wong H, Otto R, Mufarrij PW, Knight J, Akpinar H, Holmes RP, Assimos DG.

Urology. 2012 Jun;79(6):1286-9. doi: 10.1016/j.urology.2011.11.017.

32.

Glyoxal formation and its role in endogenous oxalate synthesis.

Lange JN, Wood KD, Knight J, Assimos DG, Holmes RP.

Adv Urol. 2012;2012:819202. doi: 10.1155/2012/819202. Epub 2012 Apr 8.

33.

Noncitrus alkaline fruit: a dietary alternative for the treatment of hypocitraturic stone formers.

Baia Lda C, Baxmann AC, Moreira SR, Holmes RP, Heilberg IP.

J Endourol. 2012 Sep;26(9):1221-6. doi: 10.1089/end.2012.0092. Epub 2012 Jun 4.

PMID:
22500592
34.

The impact of dietary calcium and oxalate ratios on stone risk.

Lange JN, Wood KD, Mufarrij PW, Callahan MF, Easter L, Knight J, Holmes RP, Assimos DG.

Urology. 2012 Jun;79(6):1226-9. doi: 10.1016/j.urology.2012.01.053. Epub 2012 Apr 4.

35.

The association of cardiovascular disease and metabolic syndrome with nephrolithiasis.

Lange JN, Mufarrij PW, Wood KD, Holmes RP, Assimos DG.

Curr Opin Urol. 2012 Mar;22(2):154-9. doi: 10.1097/MOU.0b013e32834fc31f. Review.

PMID:
22262248
36.

The role of renal water channels in health and disease.

Holmes RP.

Mol Aspects Med. 2012 Oct-Dec;33(5-6):547-52. doi: 10.1016/j.mam.2012.01.001. Epub 2012 Jan 12. Review.

37.

Multibacterial growth from a surgical renal stone culture: a case report and literature review.

Mufarrij PW, Lange JN, Assimos DG, Mirzazadeh M, Holmes RP.

Rev Urol. 2012;14(3-4):108-14.

38.

Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.

Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT.

Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G637-43. doi: 10.1152/ajpgi.00331.2011. Epub 2011 Dec 29.

39.

Hydroxyproline metabolism in mouse models of primary hyperoxaluria.

Knight J, Holmes RP, Cramer SD, Takayama T, Salido E.

Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F688-93. doi: 10.1152/ajprenal.00473.2011. Epub 2011 Dec 21.

40.

Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes.

Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS.

J Endourol. 2011 Nov;25(11):1781-5. doi: 10.1089/end.2011.0243. Epub 2011 Oct 21.

41.

Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria.

Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT.

PLoS One. 2011;6(10):e26021. doi: 10.1371/journal.pone.0026021. Epub 2011 Oct 6.

42.

Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers.

Knight J, Jiang J, Wood KD, Holmes RP, Assimos DG.

Urology. 2011 Aug;78(2):475.e9-475.e13. doi: 10.1016/j.urology.2011.04.008. Epub 2011 Jun 15.

43.

Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion.

Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG.

J Urol. 2011 Jul;186(1):135-9. doi: 10.1016/j.juro.2011.03.006. Epub 2011 May 14.

44.

Variability in urinary oxalate measurements between six international laboratories.

Maalouf NM, Adams Huet B, Pasch A, Lieske JC, Asplin JR, Siener R, Hesse A, Nuoffer JM, Frey FJ, Knight J, Holmes RP, Zerwekh JE, Bonny O.

Nephrol Dial Transplant. 2011 Dec;26(12):3954-9. doi: 10.1093/ndt/gfr147. Epub 2011 Mar 31.

45.

Metabolism of primed, constant infusions of [1,2-¹³C₂] glycine and [1-¹³C₁] phenylalanine to urinary oxalate.

Knight J, Assimos DG, Callahan MF, Holmes RP.

Metabolism. 2011 Jul;60(7):950-6. doi: 10.1016/j.metabol.2010.09.002. Epub 2010 Oct 30.

46.

Metabolism of fructose to oxalate and glycolate.

Knight J, Assimos DG, Easter L, Holmes RP.

Horm Metab Res. 2010 Nov;42(12):868-73. doi: 10.1055/s-0030-1265145. Epub 2010 Sep 14.

47.

Intravenous ascorbic acid infusions and oxalate production.

Holmes RP, Knight J, Assimos DG.

Metabolism. 2009 Jun;58(6):888; author reply 888-9. doi: 10.1016/j.metabol.2009.02.006. No abstract available.

PMID:
19375123
48.

Effect of soda consumption on urinary stone risk parameters.

Passman CM, Holmes RP, Knight J, Easter L, Pais V, Assimos DG.

J Endourol. 2009 Mar;23(3):347-50. doi: 10.1089/end.2008.0225.

49.

Increased protein intake on controlled oxalate diets does not increase urinary oxalate excretion.

Knight J, Easter LH, Neiberg R, Assimos DG, Holmes RP.

Urol Res. 2009 Apr;37(2):63-8. doi: 10.1007/s00240-009-0170-z. Epub 2009 Jan 29.

50.

Quantitative assessment of citric acid in lemon juice, lime juice, and commercially-available fruit juice products.

Penniston KL, Nakada SY, Holmes RP, Assimos DG.

J Endourol. 2008 Mar;22(3):567-70. doi: 10.1089/end.2007.0304.

Supplemental Content

Loading ...
Support Center